247 related articles for article (PubMed ID: 32448669)
1. Low Immunologic Risk Living Related Renal Transplant Using Very Low-Dose Antithymocyte Globulin as Induction Therapy: A Single Tertiary Hospital Experience.
Jalalonmuhali M; Ng KP; Ong CS; Lee YW; Wan Md Adnan WAH; Lim SK
Transplant Proc; 2020; 52(6):1709-1714. PubMed ID: 32448669
[TBL] [Abstract][Full Text] [Related]
2. Rabbit antithymocyte globulin (thymoglobulin): a review of its use in the prevention and treatment of acute renal allograft rejection.
Deeks ED; Keating GM
Drugs; 2009 Jul; 69(11):1483-512. PubMed ID: 19634926
[TBL] [Abstract][Full Text] [Related]
3. Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study.
Gentile G; Somma C; Gennarini A; Mastroluca D; Rota G; Lacanna F; Locatelli B; Remuzzi G; Ruggenenti P
Am J Nephrol; 2015; 41(1):16-27. PubMed ID: 25612603
[TBL] [Abstract][Full Text] [Related]
4. Induction Therapy With ATG Compared With Anti-IL2 Basiliximab in Low-Immunologic Risk Kidney Transplant Recipients.
Dedinská I; Graňák K; Vnučák M; Skálová P; Laca Ĺ; Krivuš J; Galajda P; Mokáň M
Transplant Proc; 2019 Dec; 51(10):3259-3264. PubMed ID: 31732198
[TBL] [Abstract][Full Text] [Related]
5. Basiliximab versus rabbit antithymocyte globulin as induction therapy for living-related renal transplantation: a single-center experience.
Huang HF; Zhou JY; Xie WQ; Wu JY; Deng H; Chen JH
Int Urol Nephrol; 2016 Aug; 48(8):1363-1370. PubMed ID: 27170340
[TBL] [Abstract][Full Text] [Related]
6. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
Pilch NA; Taber DJ; Moussa O; Thomas B; Denmark S; Meadows HB; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD
Ann Surg; 2014 May; 259(5):888-93. PubMed ID: 24513787
[TBL] [Abstract][Full Text] [Related]
7. Low-dose Thymoglobulin vs Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: A Prospective Randomized Trial.
Martinez-Mier G; Moreno-Ley PI; Budar-Fernández LF; Méndez-López MT; Allende-Castellanos CA; Jiménez-López LA; Barrera-Amoros DA; Aguilar-Sandoval E; De la Paz-Román M; Soto-Miranda E; Rivera-Sanchez Y; Martínez-Maldonado M
Transplant Proc; 2021 Apr; 53(3):1005-1009. PubMed ID: 32178925
[TBL] [Abstract][Full Text] [Related]
8. Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation.
Ruggenenti P; Codreanu I; Cravedi P; Perna A; Gotti E; Remuzzi G
Clin J Am Soc Nephrol; 2006 May; 1(3):546-54. PubMed ID: 17699258
[TBL] [Abstract][Full Text] [Related]
9. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up.
Laftavi MR; Alnimri M; Weber-Shrikant E; Kohli R; Said M; Patel S; Pankewycz O
Transplant Proc; 2011 Mar; 43(2):458-61. PubMed ID: 21440733
[TBL] [Abstract][Full Text] [Related]
10. The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts.
Goh BK; Chedid MF; Gloor JM; Raghavaiah S; Stegall MD
Transpl Immunol; 2012 Oct; 27(2-3):95-100. PubMed ID: 22813834
[TBL] [Abstract][Full Text] [Related]
11. Effects of Ideal Versus Total Body Weight Dosage of Rabbit Antithymocyte Globulin on Outcomes of Kidney Transplant Patients With High Immunologic Risk.
Vacha M; Gommer J; Rege A; Sanoff S; Sudan D; Harris M
Exp Clin Transplant; 2016 Oct; 14(5):511-517. PubMed ID: 26742693
[TBL] [Abstract][Full Text] [Related]
12. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.
Luan FL; Samaniego M; Kommareddi M; Park JM; Ojo AO
Transpl Infect Dis; 2010 Dec; 12(6):473-9. PubMed ID: 20576019
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
[TBL] [Abstract][Full Text] [Related]
14. Induction therapy by anti-thymocyte globulin (rabbit) versus basiliximab in deceased donor renal transplants and the effect on delayed graft function and outcomes.
Foster CE; Weng RR; Piper M; Laugenou K; Ichii H; Lakey J; Malinoski D
Transplant Proc; 2012 Jan; 44(1):164-6. PubMed ID: 22310605
[TBL] [Abstract][Full Text] [Related]
15. Basiliximab: a review of its use as induction therapy in renal transplantation.
Chapman TM; Keating GM
Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
[TBL] [Abstract][Full Text] [Related]
16. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants.
Lentine KL; Schnitzler MA; Xiao H; Brennan DC
Trials; 2015 Aug; 16():365. PubMed ID: 26285695
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of extended-duration inpatient-to-outpatient rabbit antithymocyte globulin induction in de novo kidney transplant recipients: 6-month outcomes.
Trofe-Clark J; Reese PP; Patel HJ; Jakobowski D; Goral S; Doll SL; Abt PL; Bloom RD
Transplantation; 2012 Sep; 94(5):506-12. PubMed ID: 22895613
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients.
Pennington CA; Tischer SM; Lee E; Lee S; Sindelar J; Park JM
Pharmacotherapy; 2015 Aug; 35(8):748-54. PubMed ID: 26234282
[TBL] [Abstract][Full Text] [Related]
20. Effect of Rabbit Antithymocyte Globulin on Acute and Chronic Active Antibody-Mediated Rejection After Kidney Transplantation.
Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
Transplant Proc; 2019 Oct; 51(8):2602-2605. PubMed ID: 31324482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
